My gut tells me the pace is more related to which

My gut tells me the pace is more related to which sites are on line and which ones are upcoming rather than dosing nuances. Each of the sites I’ve seen on clinical trials has a different PI listed. The study has to be a priority for those physicians and key support staff like oncology trial nurses that together are or should be actively looking for patients to consent. Dosing is to be determined, doctors may be more persuaded by the research on CCR5 and Cancer, the logic behind purported mechanism of action etc rather than “this is two arm, woe betide patients stuck with 350 mg as I am convinced before the trial starts it will fail.” Patients are not very well equipped to get into those weeds and are looking to physician guidance, which, distilled will be “very real potential benefit, negligible risk to try.”

It is realistic to expect a dose response (700 mg better than 350 mg) but I suspect 350 mg to be far from a failure and demonstrated dose response will only add to approval criteria logic.